Effects of Carvedilol Combined With Nicorandil on Plasma Heme Oxygenase 1,Immunity/Inflammation and Oxidative Stress in Patients With Coronary Heart Disease
Yue Huijuan
Zhengzhou Hospital of traditional Chinese Medicine,Zhengzhou 450000,China
Abstract:Objective To explore the effects of carvedilol combined with nicorandil on plasma heme oxygenase 1(HO-1),immune function,inflammatory response and oxidative stress in patients with coronary heart disease(CHD).Methods A total of 96 CHD patients treated were enrolled.They were divided into experimental group and control group,48 cases in each group.Both groups underwent general treatment.The control group was treated with nicorandil,while experimental group was treated with carvedilol on basis of control group.The curative effect,cardiac function,levels of HO-1,matrix metalloproteinase-9(MMP-9),immune function,inflammatory response and oxidative stress indexes were compared between the two groups.Results After treatment,the total response rate of experimental group was higher than that of control group(93.75% vs 79.17%)(P<0.05).The improvement of cardiac function indexes in experimental group was better than that in control group(P<0.05).HO-1 level in experimental group was higher than that in control group,while MMP-9 level was lower than that in control group(P<0.05).The levels of C-reactive protein(CRP),interleukin 6(IL-6)and tumor necrosis factor-α(TNF-α)in experimental group were lower than those in control group(P<0.05).The levels of CD4+ and CD4+/CD8+ in experimental group were higher than those in control group,while levels of CD8+,immunoglobulin A(IgA),IgG and IgM were lower than those in control group(P<0.05).The levels of superoxide dismutase(SOD)and glutathione peroxidase(GSH-Px)in experimental group were higher than those in control group,while level of malondialdehyde(MDA)was lower than that in control group(P<0.05).Conclusion The clinical curative effect of carvedilol combined with nicorandil is better on CHD patients,which can regulate immunity,reduce inflammation and improve oxidative stress.
[1] Houston M.The role of noninvasive cardiovascular testing,applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease[J].Ther Adv Cardiovasc Dis,2018,12(3):85-108. [2] 吴孟娜,年士艳,叶丹,等.冠心病风险评估模型构建的进展[J].分子诊断与治疗杂志,2020,12(7):839-842. [3] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694. [4] 顾文娟,张荣,赵婷婷.通心络胶囊联合阿托伐他汀治疗冠心病的疗效及其对血清cTnI、cTnT、hs-CRP水平的影响[J].心血管康复医学杂志,2020,29(4):471-474. [5] 符红军. 艾司洛尔联合卡维地洛治疗冠心病无症状性心肌缺血患者的疗效[J].安徽医学,2019,40(11):1265-1268. [6] 孙桂强,张文龙,王文,等.卡维地洛治疗无心梗冠心病患者心绞痛的临床疗效观察[J].重庆医学,2017,46(2):241-243. [7] 吴威,张婷,蒙奕兵,等.卡维地洛联合尼可地尔治疗老年冠心病心绞痛患者的效果及对sICAM-1和MPO水平的影响[J].中国医药导报,2020,17(18):139-142. [8] Zhang M.Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention:a meta-analysis[J].Oncotarget,2016,7(50):83437-83450. [9] Guo N.Correlation between genetic polymorphisms within the MAPK1/HIF-1/HO-1 signaling pathway and risk or prognosis of perimenopausal coronary artery disease[J].Clin Cardiol,2017,40(8):597-604. [10] 王兴,吴梁安,吴茂林,等.冠心病患者血清中血红素加氧酶和同型半胱氨酸水平与患者冠脉病变程度及心血管事件的关系[J].中国卫生检验杂志,2019,29(19):2377-2379. [11] Weng Y.The association between extracellular matrix metalloproteinase inducer polymorphisms and coronary heart disease:a potential way to predict disease[J].DNA Cell Biol,2020,39(2):244-254. [12] 杨艳,朱波,乔克,等.瓜蒌薤白桂枝汤对老年冠心病患者脂代谢及血浆血红素加氧酶1和基质金属蛋白酶9水平的影响[J].世界中医药,2019,14(10):2732-2736. [13] 孙春喜,任小鹏,李建成,等.冠心病患者hs-CRP、DPP-4水平及其与冠状动脉病变程度的相关性[J].海南医学,2020,31(11):1397-1400.